SCHEMBL5003249

SCHEMBL5003249

COc1ccc(-n2c(SCCN(C)C)nnc2-c2cc(C(C)C)c(OC)c(OC)c2OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
GAA P10253 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPK1 P28482 2/20 0.38
PKM P14618 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALPG P10696 2/20 0.37
CDC25A P30304 1/20 0.37
CDC25B P30305 1/20 0.37
MAPT P10636 1/20 0.37
LMNA P02545 1/20 0.37
CRHBP P24387 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5002678 0.94 MEN1 (0.41) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL14925067 0.87 MEN1 (0.45) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL14029927 0.86 HSP90AA1 (0.58) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL5006533 0.83 TLR8 (0.45) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL5003252 0.83 GAA (0.40) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL4999441 0.79 ESR1 (0.34) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL5002675 0.78 GAA (0.39) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL14925071 0.77 KMT2A (0.40) MEN1KMT2AALDH1A1HPGDHSP90AA1
SCHEMBL5008305 0.77 RAB9A (0.31) MEN1KMT2AALDH1A1HSP90AA1HSP90AB1
SCHEMBL5003224 0.74 KMT2A (0.39) KMT2AALDH1A1HPGDHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116251-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116431-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116253-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116252-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
EP-1857446-B1 Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer NIPPON KAYAKU KK (JP) 2013-05-01 EP disclosed
US-8399464-B2 using a triazole compound; anticancer agent NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-19 US disclosed
US-20080269218-A1 Novel Hsp90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2008-10-30 US disclosed
EP-1857446-A1 NOVEL HSP90 INHIBITOR Nippon Kayaku Kabushiki Kaisha (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116252-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 MEN1 4815/4885KMT2A 3665/4885ALDH1A1 873/4885
US-20130116253-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 MEN1 4815/4885KMT2A 3665/4885ALDH1A1 873/4885
US-20080269218-A1 Novel Hsp90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 MEN1 4757/4885KMT2A 3396/4885ALDH1A1 1437/4885
US-20130116251-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 MEN1 4815/4885KMT2A 3665/4885ALDH1A1 873/4885
US-20130116431-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 MEN1 4815/4885KMT2A 3665/4885ALDH1A1 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.